NASDAQ : IRD
Opus Genetics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.67 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 305.33M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 307.82M |
| Enterprise Value | 255.22M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 83.20M |
| Shares Outstanding | 83.20M |
| Shares Change (YoY) | +116.90% |
| Shares Change (QoQ) | +28.19% |
| Owned by Insiders (%) | 7.77% |
| Owned by Institutions (%) | 60.96% |
| Float | 64.63M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 31.23 |
| Forward PS | 23.10 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 25.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.19 |
| Quick Ratio | 11.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -32.32 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -4,796.52% |
| Return on Assets (ROA) | -48.06% |
| Return on Invested Capital (ROIC) | -70.88% |
| Return on Capital Employed (ROCE) | -59.29% |
| Weighted Average Cost of Capital (WACC) | 7.22% |
| Revenue Per Employee | $352,000 |
| Profits Per Employee | -$3.84M |
| Employee Count | 28 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +60.87% |
| 50-Day Moving Average | 4.46 |
| 200-Day Moving Average | 4.19 |
| Relative Strength Index (RSI) | 40.58 |
| Average Volume (20 Days) | 1,470,347 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 13.34M |
| Short Previous Month | 13.01M |
| Short % of Shares Out | 16.03% |
| Short % of Float | 20.64% |
| Short Ratio (days to cover) | 6.66 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 9.86M |
| Gross Profit | -28.77M |
| Operating Income | -50.61M |
| Pretax Income | -107.61M |
| Net Income | -107.61M |
| EBITDA | -50.56M |
| EBIT | -50.61M |
| Loss Per Share | -$1.29 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 88.81M |
| Total Debt | 36.20M |
| Net Cash | 52.61M |
| Net Cash Per Share | $0.63 |
| Equity (Book Value) | -12.99M |
| Book Value Per Share | -0.16 |
| Working Capital | 85.09M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -40.67M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 53,000 |
| Net Borrowing | 35.00M |
| Free Cash Flow | -40.67M |
| FCF Per Share | -$0.49 |
Margins
| Measure | Value |
|---|
| Gross Margin | -291.85% |
| Operating Margin | -513.47% |
| Pretax Margin | -1,091.82% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -116.90% |
| Shareholder Yield | -116.90% |
| Earnings Yield | -34.93% |
| FCF Yield | -13.21% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $13.47 |
| Price Target Difference | 264.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | 43.71% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.4 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |